In a significant move to protect public health, the Indian government has banned 156 types of fixed dose combinations (FDCs) of drugs. These FDCs, which include medications for fever, eye infections, and other ailments, have been deemed hazardous to patient health. The Union Health Ministry indicated that an expert committee appointed by the central government, along with the DTAB, reviewed the matter and both bodies recommended that there is “no therapeutic justification for the ingredients” in the mentioned FDCs & considered these FDCs as "irrational". Some of the banned FDCs include popular brands containing Aceclofenac, Diclofenac, Mefenamic Acid, Paracetamol, Cetrizine, Levocetrizine, etc.
Why were these FDCs banned?
- Potential for harm: The combination of multiple active pharmaceutical ingredients (APIs) in FDCs can increase the risk of adverse reactions and drug interactions.
- Lack of evidence: Many FDCs were found to have insufficient evidence to support their safety and efficacy.
- Risk of misuse: FDCs can be misused by patients, leading to overdose or incorrect treatment.
The ban is expected to have a positive impact on public health by reducing the risk of adverse drug reactions and improving patient safety. However, it is important to ensure that patients have access to safe and effective alternatives for their medical needs. This step is a reminder of the importance of careful regulation of the pharmaceutical industry and the need for evidence-based medicine.
Read Further: